文献速递骨质疏松与钙磷/甲状旁腺

Pro-FHH:辅助诊断甲状旁腺相关高钙血症的风险方程

Pro-FHH: A Risk Equation to Facilitate the Diagnosis of Parathyroid-Related Hypercalcemia.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

本研究基于巴黎和奥胡斯两个前瞻性队列的回顾性分析,开发了无监督风险方程Pro-FHH,用于预测患者是否患有原发性甲状旁腺功能亢进症(PHPT)。Pro-FHH纳入血浆钙、PTH、血清骨钙素及24小时尿钙肌酐清除率比值(24h-CCCR)。巴黎队列中Pro-FHH的AUROC为0.961,高于24h-CCCR;以0.928为切点时,诊断PHPT的特异度和阳性预测值均为100%,正确分类85例PHPT中的51例,其余34例建议行基因检测,无一例FHH被错误分类。在奥胡斯独立队列中AUROC为0.951,同样高于24h-CCCR。

要点

  • Pro-FHH基于血浆钙、PTH、血清骨钙素及24h-CCCR预测PHPT。
  • 巴黎队列中Pro-FHH的AUROC为0.961,高于24h-CCCR。
  • 切点0.928时诊断PHPT特异度和阳性预测值均为100%。

核心结论

  • Pro-FHH能有效预测患者是否患有PHPT。
  • 需要前瞻性试验在更大规模人群及PTH浓度升高的患者中评估其效用。

研究设计与样本

  • 回顾性分析两个前瞻性队列,开发无监督风险方程Pro-FHH。
  • 巴黎队列纳入65例FHH和85例PHPT患者;奥胡斯队列纳入38例FHH和55例PHPT患者。
  • 研究对象为成人高钙血症且PTH浓度在正常范围内。

主要发现

  • 巴黎队列中Pro-FHH的AUROC为0.961,高于24h-CCCR。
  • 奥胡斯独立队列中Pro-FHH的AUROC为0.951,高于24h-CCCR。
  • 巴黎队列中以0.928为切点,Pro-FHH诊断PHPT的特异度和阳性预测值均为100%。
  • 该切点下正确分类85例PHPT中的51例,其余34例建议行基因检测;无一例FHH被错误分类。

关键数值与推荐

  • Pro-FHH纳入血浆钙、PTH、血清骨钙素浓度及基于24小时尿液收集计算的钙肌酐清除率比值(24h-CCCR)。
  • 巴黎队列中Pro-FHH的AUROC为0.961,24h-CCCR的AUROC低于Pro-FHH。
  • 奥胡斯队列中Pro-FHH的AUROC为0.951,24h-CCCR的AUROC低于Pro-FHH。
  • 切点值为0.928时,Pro-FHH诊断PHPT的特异度为100%,阳性预测值为100%。

临床怎么用

  • Pro-FHH可预测患者是否患有PHPT,辅助鉴别PHPT与FHH。
  • 切点0.928时,Pro-FHH判定为PHPT的患者特异度和阳性预测值均为100%。
  • 未达该切点的患者建议行基因检测以助鉴别。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Parathyroid-related hypercalcemia is due to primary hyperparathyroidism (PHPT) or to familial hypocalciuric hypercalcemia (FHH). PHPT can lead to complications that necessitate parathyroidectomy. FHH is a rare genetic disease resembling PHPT; surgery is ineffective. A reliable method for distinguishing FHH from PHPT is needed. OBJECTIVE: To develop an easy-to-use tool to predict if a patient has PHPT. DESIGN: Retrospective analysis of two prospective cohorts. Development of an unsupervised risk equation (Pro-FHH). SETTING: University hospitals in Paris, France, and Aarhus, Denmark. PARTICIPANTS: Patients (Paris: 65 with FHH, 85 with PHPT; Aarhus: 38 with FHH, 55 with PHPT) were adults with hypercalcemia and PTH concentration within normal range. MAIN OUTCOME MEASURES: Performance of Pro-FHH to predict PHPT. RESULTS: Pro-FHH takes into account plasma calcium, PTH, and serum osteocalcin concentrations, and calcium-to-creatinine clearance ratio calculated from 24-hour urine collection (24h-CCCR). In the Paris cohort, area under the receiver operating characteristic curve (AUROC) of Pro-FHH was 0.961, higher than that of 24h-CCCR. With a cutoff value of 0.928, Pro-FHH had 100% specificity and 100% positive predictive value for the diagnosis of PHPT; it correctly categorized 51 of 85 patients with PHPT; the remaining 34 were recommended to undergo genetic testing. No patients with FHH were wrongly categorized. In an independent cohort from Aarhus, AUROC of Pro-FHH was 0.951, higher than that of 24h-CCCR. CONCLUSION: Pro-FHH effectively predicted whether a patient has PHPT. A prospective trial is necessary to assess its usefulness in a larger population and in patients with elevated PTH concentration.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bertocchio JP, Tafflet M, Koumakis E, et al. Pro-FHH: A Risk Equation to Facilitate the Diagnosis of Parathyroid-Related Hypercalcemia. J Clin Endocrinol Metab. 2018. PMID: 29727008. doi:10.1210/jc.2017-02773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。